NEW YORK (GenomeWeb News) – Finnish biotech firm Biohit today announced a distribution agreement with Hefei Medicine covering China.
The deal covers the distribution and marketing of Biohit's diagnostic products. Financial and other terms of the deal were not disclosed.
Among the products covered by today's announcement are Biohit's GastroPanel blood-based biomarker tests. The tests are for screening and diagnosing Helicobacter pylori.
Last month, Biohit announced an agreement to purchase Euroclone Gastro, a company focused on gastrointestinal diagnostics.